Articles from McKesson Corporation

The Board of Directors of McKesson Corporation (NYSEMCK) yesterday declared a regular dividend of 71 cents per share of common stock. The dividend will be payable on April 1, 2025, to stockholders of record on March 3, 2025.

Guided by McKesson’s core belief that the patient comes first, McKesson Amplify is a strategic initiative intended to help protect critical pharmacy services and elevate the pharmacy profession by strengthening the voice of the industry. Through McKesson Amplify, the company has committed to awarding dedicated funding to eligible state pharmacy associations across all 50 states to help meet association advocacy goals.

McKesson Corporation (NYSEMCK) reported today that on December 30, 2024 it has closed the transaction announced in September 2024 to sell its Canada-based Rexall and Well.ca businesses to Birch Hill Equity Partners, a Canadian private equity firm. This transaction enables the Company to focus capital deployment and prioritize investments expanding its strategic oncology and biopharma growth platforms.

McKesson Corporation (NYSEMCK) will release its third quarter fiscal 2025 financial results after market close on Wednesday, February 5, 2025. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results.

McKesson Corporation (NYSEMCK) has released its fiscal 2025 second quarter financial results. Results can be accessed on McKesson’s Investor Relations website at investor.mckesson.com/financials/quarterly-results.

The Board of Directors of McKesson Corporation (NYSEMCK) yesterday declared a regular dividend of 71 cents per share of common stock. The dividend will be payable on January 2, 2025, to stockholders of record on December 2, 2024.

InspiroGene™ by McKesson, a dedicated business focused solely on supporting the commercialization of cell and gene therapies (CGTs), today announced the publication of its inaugural 2024 Cell and Gene Therapy Report: Advancing the Future of Medicine.

McKesson Corporation today announced the launch of InspiroGene™ by McKesson (“InspiroGene”), a dedicated business focused solely on supporting the commercialization of cell and gene therapies (CGTs). With a scalable, flexible suite of services and an experienced leadership team, InspiroGene enables manufacturers, payers, and providers to navigate the complex CGT commercialization landscape to ensure patients can access the life-changing treatments they need.

McKesson Corporation (NYSEMCK) will release its second quarter fiscal 2025 financial results after market close on Wednesday, November 6, 2024. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results.

McKesson Corporation (NYSEMCK) announced today that it has signed an agreement to sell its Canada-based Rexall and Well.ca businesses to Birch Hill Equity Partners, a Canadian private equity firm.

McKesson Corporation (NYSEMCK) announced today that it signed a definitive agreement to acquire a controlling interest in Community Oncology Revitalization Enterprise Ventures, LLC (Core Ventures). Core Ventures, a business and administrative services organization, was established by Florida Cancer Specialists & Research Institute, LLC (FCS), a leading physician-owned community oncology practice. FCS physicians will continue to retain a minority interest in Core Ventures.

McKesson Corporation (NYSEMCK) has released its fiscal 2025 first quarter financial results. Results can be accessed on McKesson’s Investor Relations website at investor.mckesson.com/financials/quarterly-results.

The Board of Directors of McKesson Corporation (NYSEMCK) yesterday declared a regular dividend of $0.71 per share of common stock, a 15% increase from $0.62 per share in the prior quarter. The dividend will be payable on October 1, 2024, to stockholders of record on September 2, 2024.

McKesson Corporation today released its Impact Report for fiscal year 2024 (FY24), showcasing the company’s ongoing commitment to its purpose of Advancing Health Outcomes for All®.

McKesson Corporation (NYSEMCK) will release its first quarter fiscal 2025 financial results after market close on Wednesday, August 7, 2024. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results.

This week, McKesson Corporation, Health Mart, and Health Mart Atlas, hosted nearly 2,700 attendees including independent pharmacy owners and their staff at the 2024 McKesson ideaShare conference in New Orleans. Attendees discovered new ways to innovate and thrive through three days of engaging sessions, more than 30 continuing education courses, peer-to-peer connection opportunities, and 150 exhibitors from across the industry.

McKesson Corporation (NYSEMCK) announced today that the McKesson board of directors has elected Dr. Deborah Dunsire as a director and member of the Compensation and Talent Committee and Finance Committee, effective June 3, 2024.

McKesson Corporation (NYSEMCK) has released its fiscal 2024 fourth quarter financial results. Results can be accessed on McKesson’s Investor Relations website at investor.mckesson.com/financials/quarterly-results.

The Board of Directors of McKesson Corporation (NYSEMCK) yesterday declared a regular dividend of 62 cents per share of common stock. The dividend will be payable on July 1, 2024, to stockholders of record on June 3, 2024.

McKesson Corporation today announced the launch of Project Oasis, a new initiative aimed at advancing health equity for at-risk populations in underserved communities. Led by McKesson's Global Impact Organization and Community Pharmacy & Health, Project Oasis seeks to identify and address pharmacy deserts, particularly in urban areas where residents face significant challenges in accessing essential pharmacy services.

McKesson Corporation (NYSEMCK) will release its fourth quarter and full year fiscal 2024 financial results after market close on Tuesday, May 7, 2024. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results.

Registration is now open for McKesson ideaShare in New Orleans from June 23–26, 2024. The annual event is the destination for community pharmacists to come together to strengthen the overall health of pharmacy and elevate the role they play in people’s lives. Attendees can expect a comprehensive lineup of educational sessions, networking opportunities, and hands-on exhibit experiences. McKesson ideaShare will culminate by celebrating the Health Mart Pharmacy of the Year ahead of a closing concert headlined by Harry Connick, Jr.

For the eighth consecutive year, McKesson has received approval from the Centers for Medicare & Medicaid Services (CMS) to participate in the Merit-based Incentive Payment System (MIPS) as a Qualified Clinical Data Registry (QCDR). The designation enables healthcare practices and providers utilizing iKnowMed℠ electronic health record (EHR) to efficiently submit data directly to CMS without engaging a separate registry vendor, streamlining data submission and minimizing administrative burden.

McKesson Corporation (NYSEMCK) has released its fiscal 2024 third quarter financial results. Results can be accessed on McKesson’s Investor Relations website at investor.mckesson.com/financials/quarterly-results.

The Board of Directors of McKesson Corporation (NYSEMCK) yesterday declared a regular dividend of 62 cents per share of common stock. The dividend will be payable on April 1, 2024, to stockholders of record on March 1, 2024.

McKesson Corporation (NYSEMCK) will present at the 42nd Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco today at 9:45 AM PT (12:45 PM ET). Executive leadership will provide a company overview followed by a fireside chat.

McKesson Corporation (NYSEMCK) will release its third quarter fiscal 2024 financial results after market close on Wednesday, February 7, 2024. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results.

McKesson appoints Crystal Lennartz, Pharm.D., MBA, to President of Health Mart®, an independent pharmacy franchise, and Health Mart Atlas™, a pharmacy services administrative organization (PSAO).

McKesson Corporation (NYSEMCK) has released its fiscal 2024 second quarter financial results. Results can be accessed on McKesson’s Investor Relations website at investor.mckesson.com/financials/quarterly-results.

The Board of Directors of McKesson Corporation (NYSEMCK) yesterday declared a regular dividend of 62 cents per share of common stock. The dividend will be payable on January 2, 2024, to stockholders of record on December 1, 2023.

McKesson Corporation (NYSEMCK) will release its second quarter fiscal 2024 financial results after market close on Wednesday, November 1, 2023. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results.

McKesson Corporation (NYSEMCK) has released its fiscal 2024 first quarter financial results. Results can be accessed on McKesson’s Investor Relations website at investor.mckesson.com/financials/quarterly-results.

The Board of Directors of McKesson Corporation (NYSEMCK) declared on July 21, 2023 a regular dividend of $0.62 per share of common stock, a 15% increase from $0.54 per share in the prior quarter. The dividend will be payable on October 2, 2023, to stockholders of record on September 1, 2023.

McKesson Corporation (NYSEMCK) will release its first-quarter fiscal 2024 financial results after market close on Wednesday, August 2, 2023. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results.

More than 2,800 attendees including pharmacists, independent pharmacy owners, technicians, exhibitors and McKesson experts came together last week at the 2023 McKesson ideaShare conference in Las Vegas. The annual event, which is hosted by McKesson Corporation, Health Mart, and Health Mart Atlas, is the leading community pharmacy conference designed to help independent pharmacy owners and their staff discover new ways to help their pharmacy innovate and thrive. This year’s meeting delivered a comprehensive and engaging program with increased clinical and business educational opportunities and a new pharmacy technician track.

McKesson, a diversified healthcare services company, today announced the launch of Foster & Thrive™, a curated private brand of over-the-counter (OTC) health and wellness products. Launching Foster & Thrive unifies the company’s private brand portfolio—consolidating Health Mart® and Sunmark® branded OTC products—to offer expanded availability through increased production volumes and efficiencies that will help meet evolving patient needs and growing demand.

McKesson released its latest Impact Report for fiscal years 2022 and 2023, showcasing our ongoing commitment to advancing health outcomes for all. The report details McKesson’s continued efforts to track, measure and communicate our progress in achieving our corporate purpose, with a focus on how we are making an impact with our people, partners, community and planet.

McKesson Corporation (NYSEMCK) (the “Company”) today announced that its previously announced offer to purchase for cash (the “Tender Offer”) any and all of its outstanding 3.796% Notes due 2024 (the “2024 Notes”) expired at 5:00 p.m., New York City time, on June 13, 2023 (the “Expiration Time”). As of the Expiration Time, $270,994,000, or 29.52%, of the $918,070,000 aggregate principal amount outstanding of the 2024 Notes had been validly tendered and not validly withdrawn (not including any amount of 2024 Notes submitted pursuant to guaranteed delivery procedures set forth in the Offer to Purchase, dated as of June 7, 2023 (the “Offer to Purchase”)), and the related notice of guaranteed delivery (together with the Offer to Purchase, the “Offer Documents”). Payment for the 2024 Notes validly tendered and accepted for purchase is expected to be made on June 16, 2023 (the “Settlement Date”).

McKesson Corporation (NYSEMCK) (the “Company”) today announced the pricing terms of its previously announced offer to purchase for cash (the “Tender Offer”) any and all of its outstanding 3.796% Notes due 2024 (the “2024 Notes”). The Tender Offer is being made pursuant to the terms and subject to the conditions set forth in the Offer to Purchase, dated as of June 7, 2023 (the “Offer to Purchase”) and the related notice of guaranteed delivery (together with the Offer to Purchase, the “Offer Documents”).

McKesson Corporation (NYSEMCK) (the “Company”) today announced that it has commenced an offer to purchase for cash (the “Tender Offer”) any and all of its outstanding 3.796% Notes due 2024 (the “2024 Notes”). The Tender Offer is being made pursuant to the terms and subject to the conditions set forth in the Offer to Purchase, dated as of June 7, 2023 (the “Offer to Purchase”) and the related notice of guaranteed delivery (together with the Offer to Purchase, the “Offer Documents”).

McKesson Corporation (NYSEMCK) has released its fiscal 2023 fourth-quarter financial results. Results can be accessed on McKesson’s Investor Relations website at investor.mckesson.com/financials/quarterly-results.

The Board of Directors of McKesson Corporation (NYSEMCK) yesterday declared a regular dividend of 54 cents per share of common stock. The dividend will be payable on July 3, 2023, to stockholders of record on June 1, 2023.

McKesson Corporation (NYSEMCK) will release its fourth-quarter and full-year fiscal 2023 financial results after market close on Monday, May 8, 2023. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results.

For the seventh consecutive year, McKesson has received approval from The Centers for Medicare & Medicaid Services (CMS) to participate in the Merit-based Incentive Payment System (MIPS) as a Qualified Clinical Data Registry (QCDR). The designation enables iKnowMed℠ electronic health record (EHR) users to efficiently submit data directly to CMS without engaging a separate registry vendor, streamlining data submission and minimizing administrative burden.

McKesson Corporation (NYSEMCK) has released its fiscal 2023 third-quarter financial results. Results can be accessed on McKesson’s Investor Relations website at investor.mckesson.com/financials/quarterly-results.

The Board of Directors of McKesson Corporation (NYSEMCK) yesterday declared a regular dividend of 54 cents per share of common stock. The dividend will be payable on April 3, 2023, to stockholders of record on March 1, 2023.

McKesson Corporation today announced that the company has received approval by the Science Based Targets initiative (SBTi) for its near-term climate change targets that contribute to reducing its Greenhouse Gas (GHG) emissions. McKesson joins more than 2,000 companies committed to setting and achieving targets to reduce GHG emissions that are aligned to the goal of limiting global temperature rise to 1.5°C.

McKesson Corporation (NYSEMCK) will release its third-quarter fiscal 2023 financial results after market close on Wednesday, February 1, 2023. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results.

McKesson Corporation (NYSEMCK) has released its fiscal 2023 second-quarter financial results. Results can be accessed on McKesson’s Investor Relations website at investor.mckesson.com/financials/quarterly-results.

The Board of Directors of McKesson Corporation (NYSEMCK) yesterday declared a regular dividend of 54 cents per share of common stock. The dividend will be payable on January 3, 2023, to stockholders of record on December 1, 2022.

McKesson Corporation has opened a new state-of-the-art pharmaceutical distribution center in Jeffersonville, Ohio, centrally located between Cincinnati and Columbus. The new facility will distribute pharmaceutical, over-the-counter (OTC) and home healthcare (HHC) products as well as consumer packaged goods (CPG) to customers across Ohio, Indiana, Kentucky, Michigan, Pennsylvania and West Virginia.

Thought leaders from McKesson will play a major role in the upcoming 2022 Association for Value-Based Cancer Care (AVBCC) Summit, speaking on a wide range of topics that showcase their extensive knowledge of the changing healthcare landscape and oncology’s transformation to value-based care. The Summit, to be held Oct. 19-21, 2022, in New York City, is an invitational forum that provides invaluable access to more than 200 diverse experts representing every stakeholder of the cancer care ecosystem.

McKesson Corporation (NYSEMCK) today announced that it has signed an agreement in principle to extend its partnership with CVS Health to distribute pharmaceuticals to mail order and specialty pharmacies, retail pharmacies and distribution centers through June 2027.

McKesson Corporation (NYSEMCK) today announced that it has signed a definitive agreement to acquire Rx Savings Solutions (RxSS), a prescription price transparency and benefit insight company that offers affordability and adherence solutions to health plans and employers, reaching more than 17 million current patients.

McKesson Corporation (NYSEMCK) today announced that LeAnn B. Smith has been selected to become executive vice president and chief human resources officer (CHRO). Ms. Smith will succeed Tracy L. Faber, McKesson’s current CHRO, who will be retiring after an accomplished 11-year tenure with McKesson. These changes are expected to be effective December 1, 2022.

McKesson Corporation (NYSEMCK) has released its fiscal 2023 first-quarter financial results. Results can be accessed on McKesson’s Investor Relations website at investor.mckesson.com/financials/quarterly-results.

The Board of Directors of McKesson Corporation (NYSEMCK) declared on July 22, 2022 a regular dividend of $0.54 per share of common stock, a 15% increase from $0.47 per share in the prior quarter. The dividend will be payable on October 3, 2022, to stockholders of record on September 1, 2022.

McKesson Corporation (NYSEMCK) will release its first quarter fiscal 2023 financial results after market close on Wednesday, August 3, 2022. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results.

McKesson Corporation (NYSEMCK) and HCA Healthcare, Inc. NYSE: HCANYSEHCA)

McKesson Corporation (NYSEMCK) has released its fiscal 2022 fourth-quarter financial results. Results can be accessed on McKesson’s Investor Relations website at investor.mckesson.com/financials/quarterly-results.

AmerisourceBergen (NYSEABC), Cardinal Health NYSE: CAHNYSECAH)(NYSE: MCKNYSEMCK announced today that they have reached an agreement with the Washington Attorney General, under which the distributors will pay up to $518 million to the State of Washington and its participating subdivisions to resolve opioid-related claims. This amount is consistent with Washington’s allocation under the previously announced comprehensive agreement to settle the vast majority of the opioid lawsuits filed by state and local governmental entities, as well as certain attorneys’ fees and costs.

The Board of Directors of McKesson Corporation (NYSEMCK) yesterday declared a regular dividend of 47 cents per share of common stock. The dividend will be payable on July 1, 2022, to stockholders of record on June 1, 2022.

McKesson Corporation (NYSEMCK) today announced that it has closed the transaction announced in November 2021 to sell its UK businesses to AURELIUS. This is another important step in advancing McKesson’s commitment to streamline the business and fully exit the European region.

McKesson Corporation (NYSEMCK) announced today that the McKesson board of directors has elected W. Roy Dunbar as director and member of the Audit and Governance Committees, effective April 1, 2022. With the election of Dunbar, McKesson’s board of directors increases from 11 to 12 members, 11 of whom are independent.

McKesson Corporation (NYSEMCK) has released its fiscal 2022 third-quarter financial results. Results can be accessed on McKesson’s Investor Relations website at investor.mckesson.com/financials/quarterly-results.

For the ninth consecutive year, McKesson Corporation is honored as one of the “Best Places to Work for LGBTQ+ Equality” by the Human Rights Campaign (HRC) Foundation. McKesson achieved 100 percent on the HRC’s 2022 Corporate Equality Index (CEI), a nationally recognized benchmarking report on corporate policies and practices in support of lesbian, gay, bisexual, transgender, and queer (LGBTQ+) workplace equality.

The Board of Directors of McKesson Corporation (NYSEMCK) yesterday declared a regular dividend of 47 cents per share of common stock. The dividend will be payable on April 1, 2022, to stockholders of record on March 1, 2022.

McKesson Corporation (NYSEMCK) announced today that the McKesson board of directors elected James H. Hinton and Kathleen Wilson-Thompson as directors on Jan. 13, 2022. McKesson expects that the board will appoint Hinton to the Compliance Committee and Governance Committee and Wilson-Thompson to the Compensation Committee and Governance Committee. With the election of Hinton and Wilson-Thompson, McKesson’s board of directors increases from 9 to 11 members.

McKesson Corporation (NYSEMCK) will release its third quarter fiscal 2022 financial results after market close on Wednesday, February 2, 2022. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results.

McKesson Corporation (NYSEMCK) today announced that it has entered into an agreement to sell its Austrian business to Quadrifolia Management GmbH (“Quadrifolia”). The transaction includes the sale of McKesson Austria’s Herba Chemosan Apotheker-AG, together with Sanova Pharma GesmbH. The transaction is expected to close in fiscal 2022, subject to customary closing conditions, including receipt of required regulatory approvals.

McKesson Corporation (NYSEMCK) today will host an Investor Day beginning at 1:00 p.m. ET, where executive leadership will provide an overview of the company’s progress towards its goal of delivering sustainable growth and details around the company’s long-term financial outlook.

McKesson Corporation (NYSEMCK) will host an Investor Day on Wednesday, December 8, 2021 from 1:00 PM to 4:00 PM ET in New York City. The meeting will feature presentations by McKesson’s leadership team and a live Q&A session with chief executive officer Brian Tyler and chief financial officer Britt Vitalone. Management will provide an overview of the company’s progress towards its goal of delivering sustainable growth and details around the company’s long-term financial outlook.

McKesson Corporation has opened a new pharmaceutical distribution center in Holt, Mich., seven miles south of Lansing. The facility will add more than 80 full-time jobs to the region, including day and night shifts offering competitive pay and benefits.

McKesson Corporation (NYSEMCK) has released its fiscal 2022 second-quarter financial results. Results can be accessed on McKesson’s Investor Relations website at investor.mckesson.com/financials/quarterly-results.

McKesson Corporation (NYSEMCK) today announced that it has entered into an agreement to sell its UK businesses to AURELIUS, a pan-European asset management group with offices in Munich, London, Stockholm, Madrid, Amsterdam, Milan and Luxembourg. The transaction includes the sale of McKesson UK businesses LloydsPharmacy, LloydsDirect (previously Echo by LloydsPharmacy), AAH Pharmaceuticals, LloydsPharmacy Clinical Homecare, LloydsPharmacy Online Doctor, MASTA and John Bell & Croyden. The transaction is expected to close in fiscal 2022, subject to customary closing conditions, including receipt of required regulatory approvals.